euro adhoc: Intercell AG / Board of Directors (Appointments and Changes) / Intercell names Reinhard Kandera Chief Financial Officer

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

06.03.2009

Vienna, Austria, March 6, 2009 - Intercell AG (VSE: ICLL) today
announced that Reinhard Kandera has been appointed as Chief Financial
Officer (CFO). In his new role he will be responsible for the global
Finance Function and Investor Relations of Intercell AG.

Reinhard Kandera is currently CFO of Intercell´s US subsidiary
(formerly Iomai Corporation), which was acquired in 2008. He joined
Intercell in 2001 and has held various positions within Finance
including Global Head of Investor Relations and Head of Finance and
Controlling. Reinhard Kandera has made pivotal contributions to the
successful integration of Intercell´s acquisitions in Scotland and in
the USA and has implemented all the strategic funding activities of
the company. Before joining Intercell he worked for Deutsche Bank AG.
He holds doctorate degrees in both law and finance.

The prior CFO, Werner Lanthaler, will be leaving the company with
effect from March 6 to join Evotec AG (Frankfurt Stock Exchange: EVT;
NASDAQ: EVTC) as Chief Executive Officer (CEO). Werner Lanthaler has
completed a full hand-over of his responsibilities to Reinhard
Kandera as would be expected given the long, successful working
relationship between both executives and most friendly nature of the
transition.

Werner Lanthaler contributed significantly to the success of
Intercell for more than 8 years cumulating in the approval of
Intercell´s first marketed product. Werner Lanthaler has spearheaded
a series of excellent strategic partnerships, as well as achieved
sustainable profitability and a very solid financial situation
without further funding needs for Intercell. He also made key
contributions to private venture fund raisings in the early years of
the company, the IPO in 2005, the strategic alliance with Novartis in
2007 and several transforming strategic initiatives including two
major acquisitions.

"Werner Lanthaler´s contributions were pivotal to making Intercell
one of the most successful young biotech companies globally and we
want to thank him for his outstanding work. We are glad that he will
continue to be available as a strategic advisor to the company and
wish him all the best for his future plans", stated Michel Gréco,
Chairman of the Intercell Supervisory Board

"It has been a great experience for me and the Management Board and
all employees of Intercell to build the company together with Werner.
We understand and respect his decision and we would like to express
our deep gratitude for his outstanding performance. We are very happy
that Reinhard Kandera will now take over the role of the CFO. His
experience and knowledge of all company processes make him highly
qualified for the next growth phase of Intercell", stated Gerd
Zettlmeissl, Chief Executive Officer of Intercell.

"It has always been a privilege to contribute towards making
Intercell an outstanding player in the global vaccine industry, and I
am convinced that the company is excellently positioned for its next
successful growth steps. I want to thank my colleagues and especially
our investors and business partners for their strong support over the
past 8 years, which made my time at Intercell a fantastic personal
and professional experience", stated Werner Lanthaler.

The Management Board of Intercell AG will consist of Gerd Zettlmeissl
(Chief Executive Officer), Thomas Lingelbach (Chief Operating
Officer) and Alexander von Gabain (Chief Scientific Officer) until
further appointments will be made.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

P.: +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market